Premium
P1‐411: PREDICTION OF TREATMENT RESPONSE TO DONEPEZIL USING AUTOMATED HIPPOCAMPAL SUBFIELD VOLUMES SEGMENTATION IN PATIENTS WITH MILD ALZHEIMER'S DISEASE
Author(s) -
Lim Hyun Kook,
Um Yoo Hyun,
Lee Chang Uk
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.420
Subject(s) - donepezil , receiver operating characteristic , medicine , hippocampal formation , alzheimer's disease , hippocampus , area under the curve , oncology , disease , dementia
atrophy rates using a linear mixed-effects model and from the model calculated sample sizes per arm to detect a 25% slowing of atrophy (compared to non-carriers) over 12 and 24 months with 80% power and 95% significance. Results:Demographics for trial-eligible participants are shown in the Table and atrophy rates for different regions are in the Figure. The most promising regions were the precuneus (number of subjects per arm sample size [95% confidence interval] at 12 months1⁄4798[486-1458], 24 months1⁄4403[259-702]); ventricles (12 months1⁄4834[473-2105], 24 months1⁄4442[268-894]); posterior cingulate (12 months1⁄41173 [674-2440], 24 months1⁄4469[295-929]); and angular gyrus (12 months1⁄41275[668-3425], 24 months1⁄4678[378-1591]). Conclusions:A number of brain regions, notably posterior cingulate and precuneus, provide power to track change that is comparable to global atrophy measured from ventricles. Feasible sample sizes can be obtained at 24-month follow-up. Further strategies to reduce sample size should include trial enrichment using biomarker status or participants with the same mutation (e.g. presenilin1), improving atrophy measurements with direct measures between timepoints (e.g., boundary shift integral) or combining the most sensitive regions into one summary metric.